More specifically, we hypothesize that the tumor TLR9-dependent, post-treatment weight loss is actually a surrogate marker for self-DNA-induced and TLR9-mediated inflammation that takes place at the tumor site. The gene discussed is TLR9; the disease is neoplasm.